


CORPORATE FACT SHEET




Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing, and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the body-worn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at www.intricon.com.

Revenue & EPS (continuing operation) Quarterly Trends



TTM Revenue by Market from continuing operations



Stock Performance:

IIN (Common Stock)	
Exchange	NASDAQ GM (US Dollar)
Price	\$19.80
Volume Change	89.5%
Volume	70,200
52 Week Range	\$6.05 - \$21.75
Market Cap	\$136,612
EPS from Continuing Rolling Operations	\$0.29
PE Ratio	68
Shares Outstanding	6,899,617

Data as of 12/31/2017

For more up-to-date stock performance information, visit the Investor Relations section of www.IntriCon.com.



INVESTOR CONTACT: SCOTT LONGVAL

Chief Financial Officer, Secretary & Treasurer

Phone 651-604-9526

slongval@IntriCon.com

Recent Events:

December 18, 2017

During the fourth quarter, IntriCon completed its acquisition of HHE, acquiring the remaining 80-percent stake of the DeKalb, Ill.-based, direct-to-consumer mail order hearing aid provider. Terms of the transaction included \$650,000 in cash and repayment of approximately \$1.8 million in debt to HHE's 80-percent holder. Said Gorder, "Completing the HHE acquisition gives IntriCon direct access to consumers and the emerging value-based hearing healthcare market. HHE offers a lower-priced alternative for consumers to purchase devices directly—circumventing layers of costs associated with the conventional hearing aid channel."

June 22, 2017

The Company announced that it has completed phase one, as anticipated, of the introduction of its advanced digital hearing devices into Hearing Help Express' (HHE) product line. IntriCon introduced its first digital hearing device, the EarMate 4220, into the HHE portfolio in March 2017, and just recently completed phase one of the digital offering by adding the Apollo 6200, the Apollo 6310 and the Ranger 7610 digital hearing aids. "Digital hearing aids provide superior clarity and a better listening experience over their analog counterparts," said Mark S. Gorder, president and chief executive officer of IntriCon. "Through HHE we're now able to offer a lower-priced alternative for consumers to purchase technically advanced digital devices directly—circumventing layers of costs associated with the conventional hearing aid channel."

Financial Update:

February 12, 2018

For the 2017 fourth quarter, the company reported net sales of \$22.2 million, up 25.2 percent from \$17.7 million in the prior-year period. The increase was primarily due to year-over-year revenue gains from IntriCon's largest medical customer and continued traction in value hearing health. IntriCon posted net income attributable to shareholders of \$518,000, or \$0.07 per diluted share, versus a net loss attributable to shareholders of (\$1.8) million, or (\$0.27) per share, for the 2016 fourth quarter. "Our medical and value hearing health businesses continue to drive strong top- and bottom-line performance, leading to record annual sales," said Mark S. Gorder, president and chief executive officer of IntriCon.

Corporate Governance:

Mark S. Gorder	President, CEO & Founder
J. Scott Longval	CFO, Secretary & Treasurer
Mike Geraci	VP, Sales & Marketing
Dennis Gonsior	VP, Global Operations
Greg Gruenhagen	VP, Quality & Regulatory Affairs

Corporate Headquarters:

IntriCon Corporation	Tel: 651.636.9770
1260 Red Fox Road	Fax: 651.636.9503
Arden Hills, MN 55112	www.IntriCon.com